{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T01:46:07Z","timestamp":1780537567142,"version":"3.54.1"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T00:00:00Z","timestamp":1754265600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T00:00:00Z","timestamp":1754265600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"DOI":"10.1186\/s13063-025-08997-2","type":"journal-article","created":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T16:44:35Z","timestamp":1754325875000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Regorafenib versus local standard of care in patients with grade 2\u20133 meningioma no longer eligible for loco-regional treatments: a phase II randomized controlled trial (the MIRAGE study)"],"prefix":"10.1186","volume":"26","author":[{"given":"Alberto","family":"Bosio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Cerretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Padovan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Del Bianco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Polano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna","family":"Mandruzzato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Indraccolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renzo","family":"Manara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Librizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Caccese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Corr\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Maccari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Lonardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian Luca","family":"De Salvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Lombardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,4]]},"reference":[{"issue":"Supplement_4","key":"8997_CR1","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/neuonc\/noad149","volume":"25","author":"QT Ostrom","year":"2023","unstructured":"Ostrom QT, Price M, Neff C, Cioffi G, Waite KA, Kruchko C, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2016\u20132020. Neuro Oncol. 2023;25(Supplement_4):iv1-99.","journal-title":"Neuro Oncol"},{"issue":"2","key":"8997_CR2","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/nrneurol.2017.168","volume":"14","author":"M Preusser","year":"2018","unstructured":"Preusser M, Brastianos PK, Mawrin C. Advances in meningioma genetics: novel therapeutic opportunities. Nat Rev Neurol. 2018;14(2):106\u201315.","journal-title":"Nat Rev Neurol"},{"issue":"10","key":"8997_CR3","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1093\/neuonc\/noae082","volume":"26","author":"JZ Wang","year":"2024","unstructured":"Wang JZ, Landry AP, Raleigh DR, Sahm F, Walsh KM, Goldbrunner R, et al. Meningioma: International consortium on meningiomas consensus review on scientific advances and treatment paradigms for clinicians, researchers, and patients. Neuro Oncol. 2024;26(10):1742\u201380.","journal-title":"Neuro Oncol"},{"key":"8997_CR4","doi-asserted-by":"crossref","unstructured":"Mair MJ, Berghoff AS, Brastianos PK, Preusser M. Emerging systemic treatment options in meningioma. J Neurooncol. 2023;161:245-258.","DOI":"10.1007\/s11060-022-04148-8"},{"issue":"15_suppl","key":"8997_CR5","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1200\/JCO.2019.37.15_suppl.2007","volume":"37","author":"M Preusser","year":"2019","unstructured":"Preusser M, Silvani A, Le Rhun E, Soffietti R, Lombardi G, Sep\u00falveda JM, et al. Trabectedin for recurrent WHO grade II or III meningioma: a randomized phase II study of the EORTC brain tumor group (EORTC-1320-BTG). J Clin Oncol. 2019;37(15_suppl):2007\u20132007.","journal-title":"J Clin Oncol"},{"issue":"2","key":"8997_CR6","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s10735-020-09940-2","volume":"52","author":"S Bernatz","year":"2021","unstructured":"Bernatz S, Monden D, Gessler F, Radic T, Hattingen E, Senft C, et al. Influence of VEGF-A, VEGFR-1-3, and neuropilin 1\u20132 on progression-free: and overall survival in WHO grade II and III meningioma patients. J Mol Histol. 2021;52(2):233\u201343.","journal-title":"J Mol Histol"},{"issue":"5","key":"8997_CR7","doi-asserted-by":"publisher","first-page":"352","DOI":"10.5414\/NP300488","volume":"31","author":"M Preusser","year":"2012","unstructured":"Preusser M, Hassler M, Birner P, Rudas M, Acker T, Plate KH, et al. Microvascularization and expression of VEGF and its receptors in recurring meningiomas: pathobiological data in favor of anti-angiogenic therapy approaches. Clin Neuropathol. 2012;31(5):352\u201360.","journal-title":"Clin Neuropathol"},{"issue":"1","key":"8997_CR8","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1093\/neuonc\/nou148","volume":"17","author":"TJ Kaley","year":"2015","unstructured":"Kaley TJ, Wen P, Schiff D, Ligon K, Haidar S, Karimi S, et al. Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma. Neuro Oncol. 2015;17(1):116\u201321.","journal-title":"Neuro Oncol"},{"issue":"17","key":"8997_CR9","doi-asserted-by":"publisher","first-page":"4478","DOI":"10.1158\/1078-0432.CCR-19-4055","volume":"26","author":"S Indraccolo","year":"2020","unstructured":"Indraccolo S, De Salvo GL, Verza M, Caccese M, Esposito G, Piga I, et al. Phosphorylated acetyl-CoA carboxylase is associated with clinical benefit with regorafenib in relapsed glioblastoma: REGOMA trial biomarker analysis. Clin Cancer Res Off J Am Assoc Cancer Res. 2020;26(17):4478\u201384.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"2","key":"8997_CR10","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1093\/neuonc\/noaa156","volume":"23","author":"A Santangelo","year":"2021","unstructured":"Santangelo A, Rossato M, Lombardi G, Benfatto S, Lavezzari D, De Salvo GL, et al. A molecular signature associated with prolonged survival in glioblastoma patients treated with regorafenib. Neuro-Oncol. 2021;23(2):264\u201376.","journal-title":"Neuro-Oncol"},{"issue":"1","key":"8997_CR11","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/S1470-2045(18)30675-2","volume":"20","author":"G Lombardi","year":"2019","unstructured":"Lombardi G, De Salvo GL, Brandes AA, Eoli M, Ruda R, Faedi M, et al. Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet Oncol. 2019;20(1):110\u20139.","journal-title":"Lancet Oncol"},{"key":"8997_CR12","first-page":"9","volume":"79","author":"M Tuchen","year":"2017","unstructured":"Tuchen M, Wilisch-Neumann A, Daniel EA, Baldauf L, Pachow D, Scholz J, et al. Receptor tyrosine kinase inhibition by regorafenib\/sorafenib inhibits growth and invasion of meningioma cells. Eur J Cancer Oxf Engl 1990. 2017;79:9\u201321.","journal-title":"Eur J Cancer Oxf Engl 1990"},{"key":"8997_CR13","doi-asserted-by":"crossref","unstructured":"Sahm F, Aldape KD, Brastianos PK, Brat DJ, Dahiya S, von Deimling A, et al. CIMPACT-NOW update 8: clarifications on molecular risk parameters and recommendations for WHO grading of meningiomas. Neuro Oncol. 2025;27(2):319-330.","DOI":"10.1093\/neuonc\/noae170"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-025-08997-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-025-08997-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-025-08997-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T13:59:46Z","timestamp":1757339986000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-025-08997-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,4]]},"references-count":13,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["8997"],"URL":"https:\/\/doi.org\/10.1186\/s13063-025-08997-2","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,4]]},"assertion":[{"value":"17 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All participating patients will provide written informed consent. Local investigators, who are board-certified physicians with up-to-date Good Clinical Practice (GCP) certification, confirmed delegation, and completed training for clinical trial activities, will be responsible for obtaining informed consent. Ethics approval for this study was obtained from the Ethics Committee of the Istituto Oncologico Veneto (Padua, Italy). The study was approved on June 5th, 2024, with protocol version 1.1. The trial is registered under EuCT number 2024\u2013510954-28.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"This manuscript does not include any personally identifiable information from patients. No images or clinical details that could identify participants are presented in this report, nor will they be included in any future publications of the trial results. It is intended that the study design and main results will be published on . In addition, the results of the study may be published as scientific literature.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AB declares he has no competing interests. GC declares he has no competing interests. MP declares he has no competing interests. PDB declares he has no competing interests. MP declares he has no competing interests. SM declares he has no competing interests. SI declares he has no competing interests. RM declares he has no competing interests. GL declares he has no competing interests. MC declares he has no competing interests. MC declares he has no competing interests. MM declares he has no competing interests. SL has received honoraria for lectures, consultation, or advisory board participation from the following for-profit companies: Amgen, Merck Serono, Lilly, Servier, AstraZeneca, Incyte, Daiichi Sankyo, Bristol-Myers Squibb, MSD, Astellas Pharma, Bayer, GlaxoSmithKline, Takeda, Rottapharm Biotech, Beigene, Nimbus Therapeutics, Fosun Pharma, Roche, Pierre Fabre, GlaxoSmithKline. GDS declares he has no competing interests. GL has received honoraria for lectures, consultation, or advisory board participation from the following for-profit companies: Bayer, GlaxoSmithKline, Cecava, TME Pharma, Genenta Science, Novocure, Servier, Novartis, Janssen Oncology, Brain Health Solutions, health4u, Braun Travacare, CarThera.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"268"}}